Skip to main content
Jafron Biomedical Co.,Ltd. logo

Jafron Biomedical Co.,Ltd. — Investor Relations & Filings

Ticker · 300529 ISIN · CNE100002995 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,842 across all filing types
Latest filing 2019-10-23 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 300529

About Jafron Biomedical Co.,Ltd.

https://www.jafron.com

Jafron Biomedical Co.,Ltd. specializes in the research, development, and manufacturing of biomaterials and equipment for blood purification. The company is a primary provider of hemoperfusion technology, focusing on the production of adsorbent cartridges designed to remove specific toxins and inflammatory mediators from the bloodstream. Its core product portfolio includes the HA series of hemoperfusion cartridges, which are applied in clinical settings for end-stage renal disease, acute poisoning, critical care, and liver failure. Beyond consumables, the company develops blood purification machines and integrated treatment systems. These solutions target clinical applications in nephrology, intensive care, and hepatology. By leveraging advanced resin adsorption technology, the company provides specialized extracorporeal blood treatment options aimed at improving patient outcomes in complex medical conditions.

Recent filings

Filing Released Lang Actions
关于部分理财产品到期赎回的公告
Regulatory Filings Classification · 95% confidence The document is an announcement from a company regarding the maturity and redemption of certain financial products (理财产品). It details amounts, dates, yields, and risk management measures related to the company's use of idle funds for cash management. The document references a prior shareholders' meeting resolution authorizing the use of funds for such investments. The text is relatively short (3602 characters) and focuses on a specific financial update rather than comprehensive financial statements or full report content. It does not contain full financial statements or detailed financial analysis typical of an Interim Report or Annual Report. It is not a certification or officer attestation. The document is a regulatory announcement about the company's cash management activities and related risks, fitting best into the category of Regulatory Filings (RNS) as it is a general regulatory announcement and disclosure that does not fit other specific categories.
2019-10-23 Chinese
关于募集资金专户注销完成的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from a company about the completion of the cancellation of special accounts for raised funds related to its initial public offering (IPO). It details the use and management of the raised funds, the approval by the shareholders' meeting, and the completion of the account cancellations. The document is short (2018 characters) and primarily serves as a formal notification of a corporate action regarding capital raised and its management, rather than a full financial report or detailed financial statements. It does not contain comprehensive financial data or analysis but rather informs about the status of capital use and account closure. This fits the category of a Capital/Financing Update (CAP), which covers updates on company fundraising and capital structure changes.
2019-10-23 Chinese
关于限制性股票回购注销完成的公告
Transaction in Own Shares Classification · 95% confidence The document is an announcement regarding the completion of a restricted stock repurchase and cancellation by the company. It details the number of shares repurchased, the reasons for repurchase, the price adjustments, and the impact on the company's share capital structure. It includes references to board meetings and approvals but does not contain financial statements or quarterly/yearly financial results. The document is focused on a share repurchase and cancellation event related to restricted stock incentives. Therefore, it fits best under the category of Transaction in Own Shares (POS), which covers company buybacks or sales of its own shares.
2019-10-15 Chinese
2019年前三季度业绩预增公告
Earnings Release Classification · 95% confidence The document is a performance forecast announcement for the first three quarters of 2019, including estimated net profit growth percentages and explanations for the changes. It explicitly states that the forecast is unaudited and that detailed financial data will be disclosed in the upcoming quarterly report. The document length is short (1134 characters) and it does not contain actual financial statements or detailed financial analysis, only preliminary performance estimates. This fits the profile of an Earnings Release (ER) as it provides initial key highlights of quarterly financial results before the full report is published. 9M 2019
2019-10-14 Chinese
关于部分理财产品到期赎回及使用部分闲置自有资金进行现金管理的进展公告
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement from a company about the progress of cash management activities involving the redemption and purchase of financial products using idle funds. It includes specific dates, amounts, product types, expected yields, and risk management measures. The document is not a full financial report like an Annual Report (10-K) or Interim Report (IR), nor is it a simple announcement of a report publication. It is also not related to board changes, earnings releases, or legal proceedings. The content focuses on updates about capital usage and financing activities, specifically cash management and investment in financial products. Therefore, the document fits best under the category of Capital/Financing Update (CAP). The document length (6095 characters) supports it being a substantive update rather than a brief notice or certification. Confidence is high given the detailed financial product investment information and progress updates.
2019-09-30 Chinese
中航证券有限公司关于公司持续督导之2018年度现场核查报告
Audit Report / Information Classification · 95% confidence The document is titled as a "2018年度现场核查报告" (2018 Annual On-site Inspection Report) by the sponsor (中航证券有限公司) for the company 健帆生物科技集团股份有限公司. It details a comprehensive on-site inspection covering company governance, internal control, information disclosure, protection of company interests, use of raised funds, performance, and other important matters. The content includes detailed compliance checks, internal audit reviews, and governance assessments rather than financial statements or earnings data. It is not an annual report (10-K), interim report (IR), or earnings release (ER). It is also not a simple announcement or certification but a substantive audit-related report focusing on regulatory compliance and internal controls. This fits the definition of an Audit Report / Information (AR), which includes standalone audit reports and results of internal or regulatory inspections. The document length (4571 characters) is sufficient to contain detailed findings, not just an announcement. Therefore, the correct classification is AR with high confidence. FY 2018
2019-09-30 Chinese

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.